1. Home
  2. KURA vs CTKB Comparison

KURA vs CTKB Comparison

Compare KURA & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • CTKB
  • Stock Information
  • Founded
  • KURA 2014
  • CTKB 1990
  • Country
  • KURA United States
  • CTKB United States
  • Employees
  • KURA N/A
  • CTKB N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • KURA Health Care
  • CTKB Health Care
  • Exchange
  • KURA Nasdaq
  • CTKB Nasdaq
  • Market Cap
  • KURA 611.7M
  • CTKB 718.8M
  • IPO Year
  • KURA N/A
  • CTKB 2021
  • Fundamental
  • Price
  • KURA $8.25
  • CTKB $5.12
  • Analyst Decision
  • KURA Strong Buy
  • CTKB Strong Buy
  • Analyst Count
  • KURA 10
  • CTKB 2
  • Target Price
  • KURA $27.13
  • CTKB $9.25
  • AVG Volume (30 Days)
  • KURA 1.8M
  • CTKB 760.6K
  • Earning Date
  • KURA 02-26-2025
  • CTKB 02-27-2025
  • Dividend Yield
  • KURA N/A
  • CTKB N/A
  • EPS Growth
  • KURA N/A
  • CTKB N/A
  • EPS
  • KURA N/A
  • CTKB N/A
  • Revenue
  • KURA N/A
  • CTKB $201,210,000.00
  • Revenue This Year
  • KURA N/A
  • CTKB $7.26
  • Revenue Next Year
  • KURA $280.91
  • CTKB $8.20
  • P/E Ratio
  • KURA N/A
  • CTKB N/A
  • Revenue Growth
  • KURA N/A
  • CTKB 9.88
  • 52 Week Low
  • KURA $6.98
  • CTKB $4.66
  • 52 Week High
  • KURA $24.17
  • CTKB $9.33
  • Technical
  • Relative Strength Index (RSI)
  • KURA 47.12
  • CTKB 37.48
  • Support Level
  • KURA $7.87
  • CTKB $5.18
  • Resistance Level
  • KURA $8.55
  • CTKB $5.48
  • Average True Range (ATR)
  • KURA 0.55
  • CTKB 0.27
  • MACD
  • KURA 0.03
  • CTKB 0.01
  • Stochastic Oscillator
  • KURA 43.48
  • CTKB 27.85

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: